Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 654
- 试验地点
- 2
- 主要终点
- Prevention of acute heart failure development in acute MI patients
研究概览
简要总结
It is well-known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedance-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients hospitalized in the ICCU for acute myocardial infarction and developing acute heart failure
排除标准
- •Patients with acute myocardial infarction with clinical and radiological signs of acute heart failure at admission
结局指标
主要结局
Prevention of acute heart failure development in acute MI patients
时间窗: Three years
次要结局
- Improvement of clinical outcome in patients with lung impedance-guided treatments(Three years)